CIC
RNAM

Cornercap Investment Counsel’s Avidity Biosciences RNAM Stock Holding History

Cornercap Investment Counsel’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,703
Closed -$156K – 614
2022
Q2 		$156K Buy
+10,703
New +$159K 0.03% 501

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cornercap Investment Counsel's RNAM Position: Q3 2022 in Review

Cornercap Investment Counsel sold out of Avidity Biosciences (RNAM) in Q3 2022, closing a stake of 10,703 shares — an estimated $156K sold.

Cornercap Investment Counsel first reported a position in RNAM in Q2 2022 and held it in 1 quarter. The position peaked at $156K in Q2 2022. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

  • Cornercap Investment Counsel reported no remaining Avidity Biosciences position as of Q3 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 10,703 Avidity Biosciences shares in Q3 2022, an estimated $156K.
  • Cornercap Investment Counsel first reported a position in Avidity Biosciences in Q2 2022 and held it in 1 quarter.
  • Cornercap Investment Counsel's Avidity Biosciences position peaked at $156K in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Cornercap Investment Counsel's 13F filing for Q3 2022, filed 14 Nov 2022.